Ophthalmology Times

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented. Stay tuned for more parts and see what you missed online! https://hubs.li/Q03Q-kC_0

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months. Included in the study is a long-term follow-up period of 5 years. The company notes that safety and efficacy data will be collected over 2026 and 2027. https://hubs.li/Q03Q-hND0

🎃 Wishing our community of ophthalmologists and their families a safe and happy Halloween! 👻 Have a spooky and spec-tacular 👓 day! #Halloween #Ophthalmology #Spectacular

Topcon Healthcare will acquire Toku, Inc., according to a press release issued by the company. Toku is a healthcare artificial intelligence (AI) company that uses color fundus photographs to deliver assessments of health. The release notes that Toku’s planforms “are powered by one of the world’s largest retinal-image datasets. Toku reports that, as of the press release, the company has analyzed over 4.3 million de-identified retinal images linked to clinical data. The acquisition and integration of these platforms into Topcon’s current suite of offerings have the potential to leverage “oculomics to empower both primary care and eyecare providers with predictive, preventive health insights.” https://hubs.li/Q03QQS-70

Cataract and refractive surgery continues to evolve at a rapid pace, driven by advances in intraocular lenses (IOLs), laser technology, and surgical techniques. The Eye Care Network caught up with leading members of the ophthalmology community to discuss timely topics in this field. https://hubs.li/Q03QQX1p0

Hear from Eric Donnenfeld, MD, clinical professor of ophthalmology at NYU, about his experience with Ophthalmology Times over the past 50 years and his relationship with our first editorial director, Jack Dodick, MD. #OphthalmologyTimes #50thAnniversary #Ophthalmology

Interim 24-month data from a trial of the bimatoprost drug pad-IOL system (BIM-IOL system) showed sustained improvements in intraocular pressure (IOP) and visual acuity outcomes. The BIM-IOL system has been developed by SpyGlass Pharma, Inc. The company stated in its press release that the system is a “novel, proprietary non-bioerodible drug pads attached to SpyGlass Pharma’s intraocular lens (IOL).” https://hubs.li/Q03QvkMl0

Sponsored by Harrow. At Harrow, we believe treatment decisions should be made by physicians—not dictated by insurance coverage. That’s why the Access for All program is here—to ensure eligible patients have affordable access to treatment. With this program, we’re putting the power back in the hands of healthcare providers, so they can prescribe what’s truly best for their patients—without restrictions. 📌 Learn more: https://hubs.li/Q03Q0Qdp0 #ad #vevyeaccessforall #patientfirst #harrow

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the company’s request for approval of its prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg. https://hubs.li/Q03QQN0G0

ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY (NCT06659445) trial evaluating xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). According to the company, xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions. The company noted that xelafaslatide is the newly established nonproprietary name for ONL1204 Ophthalmic Solution following approval from the World Health Organization and the United States Adopted Names Council. https://hubs.li/Q03Qv90_0